Identification of anti-HIV agents with a novel benzo[4,5]isothiazolo[2,3-a]pyrimidine scaffold. by Okazaki, Shiho et al.
Title Identification of anti-HIV agents with a novelbenzo[4,5]isothiazolo[2,3-a]pyrimidine scaffold.
Author(s)
Okazaki, Shiho; Mizuhara, Tsukasa; Shimura, Kazuya;
Murayama, Hiroto; Ohno, Hiroaki; Oishi, Shinya; Matsuoka,
Masao; Fujii, Nobutaka




© 2015. This manuscript version is made available under the
CC-BY-NC-ND 4.0 license
http://creativecommons.org/licenses/by-nc-nd/4.0/; The full-
text file will be made open to the public on 1 April 2017 in
accordance with publisher's 'Terms and Conditions for Self-
Archiving'; This is not the published version. Please cite only






Identification of anti-HIV agents with a novel benzo[4,5]isothiazolo[2,3-a]pyrimidine scaffold 
 
Shiho Okazaki,a Tsukasa Mizuhara,a Kazuya Shimura,b Hiroto Murayama,b Hiroaki Ohno,a Shinya 
Oishi,a,* Masao Matsuoka,b Nobutaka Fujiia,* 
 
a Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan 













Shinya Oishi, Ph.D. and Nobutaka Fujii, Ph.D. 
Graduate School of Pharmaceutical Sciences 
Kyoto University 
Sakyo-ku, Kyoto, 606-8501, Japan 
Tel: +81-75-753-4551; Fax: +81-75-753-4570,  
E-mail (S.O.): soishi@pharm.kyoto-u.ac.jp; E-mail (N.F.): nfujii@pharm.kyoto-u.ac.jp
2 
ABSTRACT 
3,4-Dihydro-2H-benzo[4,5]isothiazolo[2,3-a]pyrimidine is a newly identified antiviral agent 
against human immunodeficiency virus type 1 (HIV-1) infection, derived from 3,4-dihydro-2H,6H-
pyrimido[1,2-c][1,3]benzothiazin-6-imine (PD 404182). The introduction of the hydrophobic 8-aryl 
substituent on the benzene substructure improved its anti-HIV activity, resulting in the identification 
of 6-fold more potent analogs. In addition, it was demonstrated that these isothiazolopyrimidine 
derivatives exert anti-HIV effects at an early stage of viral infection. 
 
Keywords: anti-HIV agent, isothiazolopyrimidine, PD 404182, pyrimidobenzothiazine 
 
Abbreviations: CCR5, CC chemokine receptor type 5; CXCR4, CXC chemokine receptor type 4; 
MAGI, multinuclear activation of a galactosidase indicator; NNRTIs, non-nucleoside reverse 
transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; 
INSTIs, integrase strand transfer inhibitors; PIDA, phenyliodine diacetate. 
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1. Introduction 
A variety of anti-HIV drugs targeted to each stage of the infection have been developed for the 
treatment of human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome 
(AIDS).1 In particular, highly active antiretroviral therapy (HAART) by co-administration of 
nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), protease inhibitors (PIs) and integrase strand transfer inhibitors (INSTIs) is a standard 
treatment regimen for HIV-infected patients.2 The HAART regimen strongly suppresses viral 
proliferation and has provided significant decline of morbidity and mortality,3 but a complete cure or 
eradication of HIV has not yet been achieved. Long-term administration of multiple antiretroviral 
agents causes the emergence of drug-resistant HIV variants and drug-related adverse effects,4,5 
resulting in increased risk of virologic failure and/or limitation in the treatment strategy.2 To overcome 
these problems, novel antiretroviral drugs with new mechanisms of action are now desired. Recently, 
a series of anti-HIV agents that inhibit an early stage of HIV infection are being explored, including 
the fusion inhibitor enfuvirtide,6 a CC chemokine receptor type 5 (CCR5) antagonist (maraviroc),7 
CXC chemokine receptor type 4 (CXCR4) antagonists,8,9 and CD4 mimics.10 
Previously, we and others reported 3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine 
(1, PD 404182)11-14 as a new antiviral agent against human hepatitis C virus (HCV),15,16 HIV,16-20 
simian immunodeficiency virus (SIV),16 and herpes simplex virus (HSV) (Figure 1).20 A structure-
activity relationship (SAR) study on compound 1 suggested that the 6-imino group and 7-sulfur atom 
were essential to interact with the potential target molecule(s), which was supported by a complete 
loss of its anti-HIV activity by substitution of these groups with other heteroatoms. Optimization of 
the benzene ring and the cyclic amidine moieties in the pyrimido[1,2-c][1,3]benzothiazin-6-imine 
scaffold demonstrated that the introduction of hydrophobic aryl moieties such as m-anisyl and 3,4-
methylenedioxyphenyl groups into the 9-position improved the anti-HIV activity three-fold.17,18 The 
antiviral profile of 1 indicated that the pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives inhibited 
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early-stage HIV infection including virus attachment and membrane fusion to host cells as exemplified 
by DS 5000 (adsorption inhibitor)21 and enfuvirtide (fusion inhibitor)6. Although it was suggested that 
compound 1 exerts its virucidal effect against viral particles,16,20 its antiviral mechanism of action has 
not yet been sufficiently detailed. 
During the course of our investigations of PD 404182 derivatives, 3,4-dihydro-2H-
benzo[4,5]isothiazolo[2,3-a]pyrimidine 2 was found to exhibit potent anti-HIV activity (EC50 = 0.29 
M) (Figure 1). The structure of this unprecedented scaffold was verified by X-ray crystal analysis. 
Although there have been several reports that similar isothiazolidine and thiadiazole derivatives 
exhibited anti-HIV activities as zinc finger inhibitors for HIV-1 nucleocapsid protein 7 (NCp7),22,23 
this tetrahydropyrimidine-fused heterocyclic scaffold has not been explored as a potential anti-HIV 
agent candidate. In the current study, we investigated the synthesis of benzo[4,5]isothiazolo[2,3-
a]pyrimidine derivatives and their structure-activity relationships as potent anti-HIV agents. 
 
2. Results and Discussion 
2.1. Synthesis of benzo[4,5]isothiazolo[2,3-a]pyrimidine derivatives 
Our investigation began with the synthesis of benzo[4,5]isothiazolo[2,3-a]pyrimidine scaffold 9 
having a characteristic S-N covalent bond, formed by oxidation of 2-(tetrahydropyrimidin-2-
yl)thiophenol derivative 8 (Scheme 1). Previously we reported the synthesis of PD 404182 derivative 
6 with the pyrimido[1,2-c][1,3]benzothiazin-6-imine core.17-19,24 Briefly, the oxidative amidination25 
of various benzaldehydes 3 gave the corresponding 2-phenyltetrahydropyrimidine derivative 4. SNAr-
type C-S bond formation on 4 with tert-butyl isothiocyanate afforded N-(tert-butyl)-protected 
thiazinimine 5, which was subjected to deprotection of the tert-butyl group with trifluoroacetic acid 
(TFA) to provide PD 404182 derivative 6. The subsequent TFA-mediated ethanolysis of the imino 
group in 6c-i,k,l,n generated the thiophenol precursor 8. Without isolation of the thiophenol 8, the 
desired benzo[4,5]isothiazolo[2,3-a]pyrimidines 9c-i,k,l,n were obtained after linking the thiol group 
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and cyclic amidine NH group by phenyliodine diacetate (PIDA)26-mediated oxidation. Alternatively, 
pyrimido[1,2-c][1,3]benzothiazin-6-thione derivatives 7j,m were synthesized by addition of carbon 
disulfide to derivatives 4j,m followed by SNAr-type C-S bond formation.24,27 Alkaline hydrolysis of 
the thiocarbonyl group of 7j,m followed by PIDA-mediated oxidation gave the compounds 9j,m. The 
benzo[4,5]isothiazolo[2,3-a]pyrimidine derivatives 9c-n were derivatized from benzothiazin-6-imine 
6 and the precursor 7,24 which were employed for our previous structure-activity relationship studies 
of PD 404182 derivatives.17,18 
A series of 8-aryl benzo[4,5]isothiazolo[2,3-a]pyrimidine derivatives 9a,b,o-z were also prepared 
by the identical protocol (Scheme 2).18 A Suzuki-Miyaura cross-coupling reaction of bromide 5d with 
aryl boronic acid provided compounds 5a,b,o-z. For the synthesis of 8-(pyridin-2-yl) derivative 9x, 
2-pyridinyltriolborate lithium salt was employed. Subsequent deprotection of the tert-butyl group of 
compound 5 gave the corresponding thiazinimine 6a,b,o-z. After TFA-mediated alcoholysis of 
compound 6, PIDA-mediated S-N bond formation afforded the desired 8-aryl 
benzo[4,5]isothiazolo[2,3-a]pyrimidines 9a,b,o-z. For the preparation of p-hydroxyphenyl and m-
hydroxyphenyl compounds 11a,b, the TBS and tert-butyl protecting groups in the precursors 10a,b 
were consecutively removed. Ullmann coupling of bromide 5d with azoles followed by subsequent 
manipulations afforded pyrazole and triazole derivatives 14a,b. 
 
2.2. Structure–activity relationship study of the anti-HIV activity of benzo[4,5]isothiazolo[2,3-
a]pyrimidine derivatives 
Initially, we investigated the modifications of the benzo[4,5]isothiazolo[2,3-a]pyrimidine 
derivatives at the 7-, 8- and 9-positions (Table 1). The anti-HIV activity of a series of compounds was 
evaluated by the NCK assay,28 in which the inhibition of virus attachment and membrane fusion to 
host cells during early-stage HIV infection is evaluated. The 8-phenyl modification (9a) maintained 
the potency of the lead compound 2 (EC50 = 0.30 M), while the m-anisyl (9b) and bromo (9d) 
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derivative exhibited two to three times greater anti-HIV activity (EC50 (9b) = 0.10 M, EC50 (9d) = 
0.22 M). In contrast, the methoxy (9c), trifluoromethyl (9e) and nitro (9f) groups slightly decreased 
the anti-HIV activity, and the 8-acetamide group in 9g remarkably attenuated the activity. 
Modifications at the 9-position of benzo[4,5]isothiazolo[2,3-a]pyrimidine were also unfavorable for 
anti-HIV activity. 9-Phenyl (9i), methyl (9j), methoxy (9k), bromo (9l) and trifluoromethyl (9m)-
modified derivatives showed two- to seven-fold less anti-HIV activity compared with compound 2. 
The 7,8-fused benzene (9h) (naphtho[2',1':4,5]isothiazolo[2,3-a]pyrimidine) and 7-bromo (9n) 
substituent exhibited cytotoxicity at 10 M with a loss of anti-HIV activity. 
On the basis of the initial structure-activity relationships of the benzo[4,5]isothiazolo[2,3-
a]pyrimidine derivatives, further modifications on the 8-aryl substituent were carried out (Table 2). 
First, we modified the para- and meta-positions of the 8-phenyl group in compound 9a. The methoxy 
(9o and 9b), methoxycarbonyl (9p and 9r) and nitro (9q and 9s) groups improved the anti-HIV activity 
(EC50 = 0.05–0.16 M), which was approximately two- to six-fold greater compared with compound 
2. Because the effects by introduction of electron-withdrawing and electron-donating substituents on 
the aromatic ring were similar, the electron density of the 8-phenyl group is unlikely to be the primary 
factor for the interaction with the target molecule(s). Para- and meta-hydroxy groups (11a and 11b) 
reduced the anti-HIV activity (EC50 = 1.28 and 1.47 M, respectively). The substitution of the 8-
phenyl group with a variety of hetero- and carbocyclic substructures was also investigated. The 
hydrophobic 3,4-methylenedioxyphenyl (9t), 2-naphthyl (9u), furan-2-yl (9v) and thiophen-3-yl (9w) 
groups increased the anti-HIV activity. In contrast, substitution with basic heterocycles such as 
pyridine (9x-z), pyrazole (14a) and triazole (14b) resulted in a slight decrease of the anti-HIV activity 
compared with compound 9a, suggesting that nitrogen heterocycles are not favorable at this position. 
These results indicated that favorable hydrophobic interaction(s) of the 8-aryl groups with the 
potential target molecule(s) could play important roles for determining the anti-HIV activity. 
Cytotoxic effects were not observed at 10 M except for compound 9o. 
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2.3. Mechanistic studies of anti-HIV isothiazolopyrimidine derivatives 
We executed a time of drug addition study to estimate the mechanism of action of the 
isothiazolopyrimidine derivatives (Figure 2). In our previous studies, we determined that PD 404182 
(1) and its derivatives inhibited an early stage of HIV infection.17,18 In this study, compound 2 and 
potent derivatives 9r and 9v were evaluated for their anti-HIV activity profiles compared with anti-
HIV agents including DS 5000 (adsorption inhibitor),21 enfuvirtide (fusion inhibitor),6 AZT (NRTI),29 
nevirapine (NNRTI),30 and raltegravir (integrase inhibitor).31 Isothiazolopyrimidine derivatives 2, 9r, 
and 9v had similar inhibitory profiles to that of DS 5000 and compound 1, which prevent an early 
stage of viral infection including the attachment and entry into the target cells. It should also be noted 
that both compounds 1 and 2 showed a broad spectrum of antiviral activity against RNA viruses and 
DNA viruses (data not shown). These results may suggest that these two series of compounds may 
have an identical or similar target molecule(s) or mechanism of action for the antiviral activities. 
Although a possible common viral target molecule(s) has not yet been identified,32 these derivatives 
could positively regulate the defense mechanism(s) of the host cells. 
 
3. Conclusions 
In this study, we identified a novel class of small-molecule anti-HIV agents with the 
benzo[4,5]isothiazolo[2,3-a]pyrimidine scaffold. A structure-activity relationship study of the lead 
compound 2 demonstrated that a hydrophobic aryl substituent at the 8-position of the scaffold was 
responsible for the potent anti-HIV activity. Although the improvement of the anti-HIV activity from 
2 was not satisfactory, further SAR studies would provide promising candidates with higher potency 
and favorable antiviral profiles. The similar antiviral profiles between compounds 1 and 2 suggested 
that these could possibly binds with the common potential target molecule(s) in host cells. The 
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identification of the target molecule(s) and further optimization of potent derivatives should facilitate 
the development of novel antiviral agents. 
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4. Experimental Section 
4.1. Synthesis 
4.1.1. General synthesis 
1H NMR spectra were recorded using a JEOL AL-400 or a JEOL ECA-500 spectrometer. Chemical 
shifts are reported in δ (ppm) relative to Me4Si as an internal standard. 13C NMR spectra were 
referenced to the residual solvent signal. Exact mass (HRMS) spectra were recorded on a JMS-HX/HX 
110A mass spectrometer or Shimadzu LC-ESI-IT-TOF-MS equipment. For flash chromatography, 
Wakogel C-300E (Wako) was employed. For analytical HPLC, a Cosmosil 5C18-ARII column (4.6 
 250 mm, Nacalai Tesque, Inc.) was employed with a linear gradient of CH3CN containing 0.1% 
(v/v) TFA aq. at a flow rate of 1 mL/min, and eluting products were detected by UV at 254 nm. 
Preparative HPLC was performed using a Cosmosil 5C18-ARII preparative column (20  250 mm, 
Nacalai Tesque, Inc.) with a linear gradient of CH3CN containing 0.1% (v/v) TFA aq. at a flow rate 
of 8 mL/min. The purity of the compounds was determined as no less than 95% by combustion 
analysis or HPLC analysis. 
 
4.1.2. General procedure for the synthesis of benzo[4,5]isothiazolo[2,3-a]pyrimidine from 
pyrimido[1,2-c][1,3]benzothiazin-6-imine: synthesis of 3,4-dihydro-2H-
benzo[4,5]isothiazolo[2,3-a]pyrimidine (2) 
TFA (171 μL, 2.30 mmol) was added to a suspension of PD 404182 (1) (50.0 mg, 0.230 mmol) in 
CHCl3 (2.30 mL) and EtOH (3.43 mL) dropwise. After being stirred at room temperature for 1 h, the 
mixture was quenched with Et3N (321 μL, 2.30 mmol), and PIDA (72.6 mg, 0.226 mmol) was added. 
After being stirred for 30 min at room temperature, the mixture was concentrated. Crude product was 
purified by HPLC to give the title compound 2 as colorless crystals (48.5 mg, 71%, TFA salt); mp 
200–202 °C (from Et2O–MeOH); IR (neat) cm-1: 3117-3056 (OH), 1662 (C=O), 1630 (C=N); 1H 
NMR (500 MHz, CD3OD): δ 2.30-2.35 (m, 2H, CH2), 3.67 (t, J = 5.4 Hz, 2H, CH2), 4.16 (t, J = 5.7 
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Hz, 2H, CH2), 7.63-7.66 (m, 1H, Ar), 7.84-7.87 (m, 1H, Ar), 8.04 (d, J = 8.6 Hz, 1H, Ar), 8.17 (d, J 
= 8.0 Hz, 1H, Ar); 13C NMR (125 MHz, CD3OD): δ 20.7, 39.0, 46.3, 118.3 (q, J = 293.9 Hz), 122.5, 
123.0, 125.1, 128.2, 134.7, 143.5, 156.0, 163.0 (q, J = 34.8 Hz); Anal. calcd for C12H11F3N2O2S: C, 
47.37; H, 3.64; N, 9.21. Found: C, 47.32; H, 3.80; N, 9.29. 
 
4.1.3. 9-Methyl-3,4-Dihydro-2H-benzo[4,5]isothiazolo[2,3-a]pyrimidine (9j) 
10-Methyl-3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazine-6-thione (7j) (60.0 mg, 0.242 
mmol) was suspended in 0.1N NaOH in MeOH-H2O (9:1, 4.83 mL). After being stirred under reflux 
for 12 h, the mixture was quenched with 1N HCl until pH was adjusted to 7. The whole was extracted 
with CHCl3–MeOH (95:5), and dried over MgSO4. After concentration, the residue in CHCl3 (6.04 
mL) was allowed to react with PIDA (76.3 mg, 0.237 mmol). After being stirred for 30 min at room 
temperature, the mixture was concentrated. Purification by HPLC gave the title compound 9j as 
colorless solid (4.5 mg, 6%, TFA salt); IR (neat) cm-1: 3265-3141 (OH), 1669 (C=O), 1630 (C=N); 
1H NMR (500 MHz, CD3OD): δ 2.29-2.34 (m, 2H, CH2), 2.53 (s, 3H, CH3), 3.66 (t, J = 5.7 Hz, 2H, 
CH2), 4.14 (t, J = 5.7 Hz, 2H, CH2), 7.71 (dd, J = 8.3, 1.4 Hz, 1H, Ar), 7.91 (d, J = 8.6 Hz, 1H, Ar), 
7.96 (d, J = 1.7 Hz, 1H, Ar); 13C NMR (125 MHz, CD3OD): δ 20.7, 21.1, 38.9, 46.3, 118.6 (q, J = 
255.5 Hz), 122.1, 123.0, 124.6, 136.2, 139.0, 140.6, 155.7, 162.7 (q, J = 33.6 Hz); HRMS (FAB): m/z 
calcd for C11H13N2S [M + H]+ 205.0799; found: 205.0795. 
 
4.1.4. 8-(4-Hydroxyphenyl)-3,4-dihydro-2H-benzo[4,5]isothiazolo[2,3-a]pyrimidine (11a) 
TFA (2.35 mL) was added to a mixture of N-(tert-butyl)-9-[4-(tert-butyldimethylsilyloxy)phenyl]-
3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (10a) (112.6 mg, 0.235 mmol) in a few 
drops of CHCl3 and MS4Å (528 mg, powder, activated by heating with Bunsen burner). After being 
stirred under reflux for 4 h, the mixture was added dropwise Et3N at 0 °C to adjust pH to 8–9. The 
whole was extracted with EtOAc. The extract was washed with sat. NaHCO3, brine, and dried over 
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MgSO4. Concentration gave the crude imine as pale yellow solid (73.9 mg). By use of a procedure 
similar to that described for the preparation of the compound 2 from 1, a part of the residue (20.0 mg) 
was converted to the title compound 11a as colorless solid (11.0 mg, 44% in 2 steps, TFA salt); IR 
(neat) cm-1: 3237-3066 (OH), 1684 (C=O), 1632 (C=N); 1H NMR (500 MHz, CD3OD): δ 2.31-2.35 
(m, 2H, CH2), 3.67 (t, J = 5.7 Hz, 2H, CH2), 4.15 (t, J = 6.0 Hz, 2H, CH2), 6.91-6.94 (m, 2H, Ar), 
7.60-7.63 (m, 2H, Ar), 7.86 (dd, J = 8.6, 1.1  Hz, 1H, Ar), 8.15 (d, J = 8.6 Hz, 1H, Ar), 8.19 (d, J = 
1.7 Hz, 1H, Ar); 13C NMR (125 MHz, CD3OD): δ 20.7, 39.0, 46.2, 117.1 (2C), 118.2 (q, J = 238.7 
Hz), 119.0, 120.8, 125.3, 126.7, 129.8 (2C), 130.8, 144.3, 147.7, 155.7, 160.0, 162.9 (q, J = 34.8 Hz); 
HRMS (ESI): m/z calcd for C16H15N2OS [M + H]+ 283.0905; found: 283.0908. 
 
4.2. Anti-HIV activity 
The anti-HIV activity of a series of compounds against HIV-1IIIB was determined by the NCK 
assay.28 The target cells (NCK45-β-Gal; 104 cells/well) were plated in 96-well flat microtiter culture 
plates. On the following day, the cells were inoculated with HIV-1 (60 NCK U/well, giving 60 blue 
cells after 48 h of incubation) and cultured in the presence of various concentrations of the test 
compounds in fresh medium. Forty-eight hours after viral exposure, all the blue cells stained with X-
Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) were counted in each well. The activity of 
test compounds was determined as the concentration that blocked HIV-1 infection by 50% (50% 
effective concentration [EC50]). EC50 was determined by using the following formula:  
EC50 = 10^[log(A/B)×(50 – C)/(D – C) + log(B)], 
where 
A: of the two points on the graph that bracket 50% inhibition, the higher concentration of the test 
compound,  
B: of the two points on the graph that bracket 50% inhibition, the lower concentration of the test 
compound,   
12 
C: inhibitory activity (%) at the concentration B,  
D: inhibitory activity (%) at the concentration A. 
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Table 1. Structure-activity relationships of benzo[4,5]isothiazolo[2,3-a]pyrimidine derivatives. 














2 R = H  0.29 ± 0.09   
9a R = Ph 0.30 ± 0.10 9i  R = Ph 0.56 ± 0.13 
9b R = m-anisyl 0.10 ± 0.03 9j  R = Me 0.85 ± 0.10 
9c R = OMe  0.58 ± 0.10 9k R = OMe  2.11 ± 0.48 
9d R = Br 0.22 ± 0.07 9l R = Br 1.01 ± 0.22 
9e R = CF3 1.28 ± 0.04 9m R = CF3 1.78 ± 0.24 
9f R = NO2 1.79 ± 0.44      






aEC50 values represent the concentration of the compound required to inhibit the HIV-1 infection by 
50%. The data were obtained from three independent experiments by the NCK assay. bThe compound 
inhibited the HIV-1 infection by 40% at 1.0 M. cCytotoxicity was observed at 10 M. 
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aEC50 values represent the concentration of the compound required to inhibit the HIV-1 infection by 
50%. The data were obtained from three independent experiments by the NCK assay. bCytotoxicity 
was observed at 10 M.  
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Figure 2. Time of drug addition profiles for HIV-1 infection. 
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Scheme 1. Synthesis of 7-, 8- and 9- substituted benzo[4,5]isothiazolo[2,3-a]pyrimidine derivatives. 
Reagents and conditions: (a) 1,3-propanediamine, I2, K2CO3, t-BuOH, 70 °C; (b) NaH or t-BuOK, t-
BuNCS, DMF or DMAc, -20 – 80 °C; (c) NaH, CS2, DMF, rt-80 °C; (d) TFA, MS4Å, CHCl3, reflux; 

















5c -i,k,l,n (R' = t-Bu)
























Scheme 2. Synthesis of 8-aryl benzo[4,5]isothiazolo[2,3-a]pyrimidines. Reagents and conditions: (a) 
Ar-B(OH)2, Pd(PPh3)4, Pd(dppf)Cl2·CH2Cl2, K2CO3, toluene/EtOH/H2O, reflux; (b) 2-
pyridinyltriolborate lithium salt, Pd(OAc)2, CuI, PPh3, DMF, 80 °C; (c) TFA, MS4Å, CHCl3, reflux; 
(d) TFA, CHCl3/EtOH or EtOH, rt, then Et3N, PIDA, CHCl3/EtOH or EtOH, rt; (e) pyrazole or triazole, 
CuCl, K2CO3, acetylacetone, NMP, 130 °C. 
 
